Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CFO Sells $129,729.42 in Stock

Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) CFO Adam Scott Levy sold 10,757 shares of the firm's stock in a transaction that occurred on Friday, April 11th. The shares were sold at an average price of $12.06, for a total transaction of $129,729.42. Following the completion of the sale, the chief financial officer now directly owns 215,340 shares in the company, valued at $2,597,000.40. This represents a 4.76 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Mineralys Therapeutics Stock Down 1.1 %

NASDAQ:MLYS traded down $0.15 during mid-day trading on Friday, reaching $13.35. The company's stock had a trading volume of 382,306 shares, compared to its average volume of 417,708. The stock has a fifty day moving average of $12.59 and a 200-day moving average of $12.36. Mineralys Therapeutics, Inc. has a 1 year low of $8.24 and a 1 year high of $18.38. The firm has a market capitalization of $866.09 million, a PE ratio of -3.67 and a beta of -0.39.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last posted its earnings results on Wednesday, February 12th. The company reported ($0.98) EPS for the quarter, beating analysts' consensus estimates of ($1.00) by $0.02. On average, analysts expect that Mineralys Therapeutics, Inc. will post -4.23 earnings per share for the current year.

Institutional Investors Weigh In On Mineralys Therapeutics

Several hedge funds have recently bought and sold shares of MLYS. GAMMA Investing LLC increased its holdings in Mineralys Therapeutics by 9,602.2% in the 1st quarter. GAMMA Investing LLC now owns 8,829 shares of the company's stock worth $140,000 after acquiring an additional 8,738 shares in the last quarter. Wellington Management Group LLP boosted its stake in Mineralys Therapeutics by 43.0% during the fourth quarter. Wellington Management Group LLP now owns 91,529 shares of the company's stock worth $1,127,000 after buying an additional 27,531 shares during the period. Polar Asset Management Partners Inc. boosted its position in shares of Mineralys Therapeutics by 144.7% during the 4th quarter. Polar Asset Management Partners Inc. now owns 99,100 shares of the company's stock worth $1,220,000 after purchasing an additional 58,600 shares during the period. Tema Etfs LLC acquired a new stake in shares of Mineralys Therapeutics in the fourth quarter valued at $1,102,000. Finally, Stempoint Capital LP purchased a new position in Mineralys Therapeutics during the 4th quarter valued at about $4,925,000. Hedge funds and other institutional investors own 84.46% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. HC Wainwright upped their price target on Mineralys Therapeutics from $30.00 to $42.00 and gave the company a "buy" rating in a research report on Wednesday, April 2nd. The Goldman Sachs Group lowered their target price on shares of Mineralys Therapeutics from $28.00 to $24.00 and set a "buy" rating on the stock in a research note on Thursday, February 13th. Finally, Guggenheim restated a "buy" rating on shares of Mineralys Therapeutics in a research report on Monday, February 24th.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.